Hedge Fund - Birchview Capital

In this article, we discuss 10 biotech stocks to buy according to Matthew Strobeck's Birchview Capital.

Underwriting Agreement, dated as of December 19, 2017, by and between Yield10 Bioscience, Inc. and Ladenburg Thalmann & Co. Inc.

By signing below the Reporting Person certifies that, to the best of such person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with...

Birchview Capital is a Vermont-based biosciences-focused long/short equity hedge fund founded by Dr. Matthew Strobeck in 2014. Dr. Strobeck holds a Ph.D.